PRAME expression is associated with an increased incidence of ABL tyrosine kinase domain point mutations in late CP patients
| . | PRAME detected, no. (%) . | PRAME not detected, no. (%) . |
|---|---|---|
| Mutation at entry | 8 (89) | 1 (11) |
| Mutation at any time | 11 (79) | 3 (21) |
| No mutation at entry | 5 (42) | 7 (58) |
| No mutation at any time | 2 (25) | 6 (75) |
| . | PRAME detected, no. (%) . | PRAME not detected, no. (%) . |
|---|---|---|
| Mutation at entry | 8 (89) | 1 (11) |
| Mutation at any time | 11 (79) | 3 (21) |
| No mutation at entry | 5 (42) | 7 (58) |
| No mutation at any time | 2 (25) | 6 (75) |
ABL tyrosine kinase domain (TKD) point mutation data were available for 21 patients at study entry and for 22 patients during nilotinib treatment. PRAME expression was detected in 11 (79%) of 14 patients who developed ABL TKD point mutations either prior to therapy or during therapy compared with 2 (25%) of 8 patients who never had evidence of a point mutation (P=.03). When restricted to patients with mutations at study entry only, P=.07.